A detailed history of Vanguard Group Inc transactions in Fulcrum Therapeutics, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 3,071,143 shares of FULC stock, worth $9.86 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,071,143
Previous 2,538,665 20.97%
Holding current value
$9.86 Million
Previous $24 Million 20.54%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$5.98 - $9.31 $3.18 Million - $4.96 Million
532,478 Added 20.97%
3,071,143 $19 Million
Q1 2024

May 10, 2024

BUY
$6.7 - $12.0 $125,162 - $224,172
18,681 Added 0.74%
2,538,665 $24 Million
Q4 2023

Feb 14, 2024

SELL
$3.18 - $6.86 $391,810 - $845,227
-123,211 Reduced 4.66%
2,519,984 $17 Million
Q3 2023

Nov 14, 2023

BUY
$3.25 - $6.08 $55,789 - $104,369
17,166 Added 0.65%
2,643,195 $11.7 Million
Q2 2023

Aug 14, 2023

SELL
$2.26 - $3.8 $570,564 - $959,355
-252,462 Reduced 8.77%
2,626,029 $8.67 Million
Q1 2023

May 15, 2023

BUY
$2.83 - $13.99 $2.14 Million - $10.6 Million
757,868 Added 35.74%
2,878,491 $8.2 Million
Q4 2022

Feb 10, 2023

BUY
$5.01 - $8.35 $824,300 - $1.37 Million
164,531 Added 8.41%
2,120,623 $15.4 Million
Q3 2022

Nov 14, 2022

BUY
$4.92 - $9.1 $2.1 Million - $3.88 Million
426,430 Added 27.88%
1,956,092 $15.8 Million
Q2 2022

Aug 12, 2022

BUY
$4.2 - $24.0 $108,532 - $620,184
25,841 Added 1.72%
1,529,662 $7.5 Million
Q1 2022

May 13, 2022

BUY
$9.96 - $23.65 $350,213 - $831,581
35,162 Added 2.39%
1,503,821 $35.6 Million
Q4 2021

Feb 14, 2022

BUY
$14.0 - $28.44 $3.01 Million - $6.12 Million
215,233 Added 17.17%
1,468,659 $26 Million
Q3 2021

Nov 12, 2021

BUY
$7.28 - $30.97 $2.52 Million - $10.7 Million
346,391 Added 38.19%
1,253,426 $35.4 Million
Q2 2021

Aug 13, 2021

BUY
$8.09 - $12.0 $7.34 Million - $10.9 Million
907,035 New
907,035 $9.51 Million

Others Institutions Holding FULC

About Fulcrum Therapeutics, Inc.


  • Ticker FULC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 52,038,900
  • Market Cap $167M
  • Description
  • Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystro...
More about FULC
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.